Magen OrthoMed

Company Overview

Snapshot

Founded in January 2011 by Hamid Sharim and Shmuel Beck, Magen OrthoMed operates with 1–10 employees. The company has raised $500,000 across one funding round from one investor. Magen OrthoMed is currently in the clinical trial stage for its medical devices.

Business overview

Magen OrthoMed is a Health Tech & Life Sciences company focused on developing adhesion barriers to prevent scar tissue proliferation and adhesion to anatomical structures like spinal dura, nerves, tendons, or ligaments. Its core technology involves implanting temporary synthetic barriers, such as SpineShield, TendonShield, and NerveShield, which are later removed. These products aim to reduce scar tissue formation and provide clear surgical planes for safer re-operations. The company operates in the Medical Devices sector, serving the healthcare industry in geomarkets like Europe.

Company Intelligence Q&A

What is Magen OrthoMed's primary focus?

Magen OrthoMed focuses on developing adhesion barriers to prevent scar tissue from proliferating and adhering to anatomical structures such as spinal dura, nerves, tendons, or ligaments.

Who are the founders of Magen OrthoMed?

Magen OrthoMed was co-founded by Hamid Sharim and Shmuel Beck.

What products does Magen OrthoMed offer?

Magen OrthoMed offers products such as SpineShield, TendonShield, and NerveShield, which are designed as temporary synthetic barriers to prevent scar tissue adhesion.

What is the current product development stage for Magen OrthoMed?

Magen OrthoMed's products, including SpineShield, TendonShield, and NerveShield, are currently in the clinical trial stage. These products are designed as temporary synthetic barriers to prevent scar tissue adhesion.

What is the primary market for Magen OrthoMed's products?

Magen OrthoMed targets the medical devices industry within the healthcare sector, with a focus on geomarkets such as Europe.